{"id":"W4210750855","doi":"10.1016/j.annonc.2022.01.076","title":"Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation–positive melanoma","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Roche","keywords":"Atezolizumab; Medicine; Vemurafenib; Internal medicine; Hazard ratio; Oncology; Confidence interval; Cancer; Pembrolizumab; Immunotherapy; Metastatic melanoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002014052,0.0001711416,0.0004081815,0.0001414501,0.00006290662,0.000002832984,0.0001811198,0.0001160203,0.00008973111],"category_scores_gemma":[0.00002188943,0.0001545575,0.0001069267,0.000189331,0.0001382015,0.000003531273,0.0001159986,0.00006931851,0.000002408184],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001048439,"about_ca_system_score_gemma":0.0006288007,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005148377,"about_ca_topic_score_gemma":0.0004495404,"domain_scores_codex":[0.9987359,0.0001716283,0.0003677133,0.0003268404,0.0001305328,0.0002673982],"domain_scores_gemma":[0.9992034,0.00006151409,0.0002885934,0.0002582224,0.0001219615,0.00006635077],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.03783767,0.00340214,0.01719986,0.0002158701,0.003645426,0.001345272,0.007791847,0.02161875,0.6869654,0.006603525,0.005747483,0.2076268],"study_design_scores_gemma":[0.01425533,0.07471192,0.02731262,0.0000432802,0.0001284856,0.0004690428,0.002342968,0.0003676324,0.8221746,0.0004319502,0.0571553,0.0006068733],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9892612,0.0007600511,0.00004304181,0.0003830972,0.00009686415,0.0003728251,0.0002324591,0.000005751712,0.00884472],"genre_scores_gemma":[0.9983239,0.0001497031,0.0003159332,0.0002070565,0.00003566718,0.0001197574,0.000406395,0.00001933088,0.0004222887],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2070199,"threshold_uncertainty_score":0.6302671,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03356083637505654,"score_gpt":0.3065765158893343,"score_spread":0.2730156795142777,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}